Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · NeoGenomics Laboratories (NEO)

NeoGenomics says General Counsel Alicia Olivo will leave role effective September 21, 2026

Neutral Impact 2 of 5 leadership Written later

NeoGenomics said its EVP, General Counsel and Business Development, Alicia Olivo, will cease to serve as General Counsel effective September 21, 2026. She will remain an employee until October 2, 2026 for transitional purposes, and she will be eligible for separation payments and benefits under her employment agreement. The filing does not describe a financial figure for those payments or a named successor.

Key points

  • Alicia Olivo stops serving as General Counsel effective September 21, 2026
  • Olivo remains an employee until October 2, 2026 for transitional purposes
  • Separation payments and benefits follow Section 5(b) of her employment agreement, filed with the 10-K on February 17, 2026
  • The filing does not disclose a dollar amount for separation payments or a replacement

The filing

CompanyNeoGenomics Laboratories (NEO)
Form8-K, current report
Filed with the SECAug 11, 2026, 4:10 PM ET
Accession number0001628280-26-055697

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.